Navigation Links
New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
Date:8/21/2008

Cylex's ImmuKnow(R) assay suggests clinical potential in independent study

of pediatric liver transplant patients

COLUMBIA, Md., Aug. 21 /PRNewswire/ -- Israeli et al.,* in an article just published in the peer-reviewed journal Liver Transplantation, have further developed our understanding of the clinical potential of monitoring cell- mediated immunity in pediatric liver-transplant patients post-transplantation.

Working in a cooperative group involving several institutions in Petach- Tikva and Tel Aviv in Israel, Israeli and his colleagues focused on the use of the Cylex ImmuKnow assay to monitor cell-mediated immunity post-transplant in pediatric patients between 1 and 18 years of age who had undergone liver transplantation.

In adult transplant patients, cell-mediated immunity as measured using the ImmuKnow assay is classified into three categories, as defined in the product's package insert. However, a prior study in pediatric renal transplant patients reported that ATP levels defining equivalent categories among these pediatric patients were significantly lower than among comparable adult patients, and recommended the following pediatric categories:

-- a pediatric "low" of <175 ng ATP/mL

-- a pediatric "moderate" of between 175 and 395 ng ATP/mL

-- a pediatric "strong" of >395 ng ATP/mL

Data from the study by Israeli et al. support these lower categories for cell-mediated immunity in pediatric transplant patients, and in liver transplant patients in particular:

-- The median ATP level in this group of 28 samples from pediatric liver transplant patients was 300 +/- 102 ng/mL.

-- Half of the patient assays (between the 25th and 75th percentiles) were found to be between 251 and 387 ng ATP/mL.

-- There was no significant difference between the immune function of stable pediatric liver transplant patients who were <12 years of age as opposed to those >12 years of age.

-- During clinical quiescence, ImmuKnow assay results correlated with clinical status of the patients for 23/28 samples (82 percent), with correlation being defined as within a normal range of 195-395 ng ATP/mL.

"Cylex continues to be interested in understanding the categorization of cell-mediated immune status in the pediatric transplant patient community," stated Brad L. Stewart, president of Cylex. "Although the appropriate categorization of immune status is well-defined in the adult community, there are fewer data available on the application of the ImmuKnow assay in pediatric patients. Cylex will continue to support studies that seek to resolve questions about the use of ImmuKnow as a tool to monitor pediatric transplant patients and their levels of cell mediated immunity."

* Israeli M, Klein T, Sredni B, et al. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transplant. 2008;14:893-898.

About ImmuKnow(R)

ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The uses of the ImmuKnow assay as described in these studies have not been approved or cleared by the FDA. The Company may use data from these or similar studies to support future FDA marketing applications for similar indications.

About Cylex, Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products intended to illuminate immunity. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. The Company is based in Columbia, MD, USA.


'/>"/>
SOURCE Cylex(TM)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
2. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
3. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
4. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
6. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
7. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
8. Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
9. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
10. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 ... and Others The global anti-obesity drugs market ... first half of the forecast period and CAGR of 38.7% in ... to grow at a CAGR of 32.8% from 2016 to 2027. ... in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... ... ... and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is ... a devoted woman of faith. , “Becoming a parent changes you. In my case, ... for years, but actually doing it might have been a while in coming if it ...
(Date:1/20/2017)... ... , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of ... Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who ... Hardy , “While sitting up in bed, I felt a pounding headache. It was ...
Breaking Medicine News(10 mins):